Perceptions and Attitudes Towards COVID-19 Vaccination Amongst Pregnant and Postpartum Individuals

Molly R. Siegel, MD<sup>1, 2</sup>, Mario I. Lumbreras-Marquez, MBBS<sup>3</sup>, MMSc, Kaitlyn James PhD<sup>1, 2</sup>, Brandon R. McBay<sup>4</sup>, Kathryn J. Gray, MD, PhD<sup>2, 5</sup>, Julianna Schantz-Dunn, MD<sup>2, 5</sup>, Khady Diouf, MD<sup>2, 5\*</sup> and Ilona T. Goldfarb, MD, MPH<sup>1, 2\*</sup>

<sup>1</sup> Department of Obstetrics, Gynecology, and Reproductive Biology, Massachusetts General Hospital, Boston, MA

\*Both Drs. Diouf and Goldfarb have contributed to this project to meet the role of senior author Corresponding Author: Molly R. Siegel, MD Mailing address: 55 Fruit Street, Austen 4, Boston, MA 02114. Telephone: (617) 724-9408. Fax: (617) 724-3498. Email: mrsiegel@partners.org.

Word Count: Text is 2464 words and 10 pages. There are 2 figures and 1 table.

Conflicts of Interest: The authors report no conflicts of interest.

<u>Financial Disclosures</u>: Dr. Gray has consulted for Illumina Inc,, Aetion, and BillionToOne outside the scope of the submitted work. No other financial disclosures are reported by the authors of this paper.

<sup>&</sup>lt;sup>2</sup> Harvard Medical School, Boston, MA

<sup>&</sup>lt;sup>3</sup> Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women's Hospital, Boston, MA

<sup>&</sup>lt;sup>4</sup> Department of Social and Behavioral Sciences, Harvard T.H.Chan School of Public Health, Boston, MA

<sup>&</sup>lt;sup>5</sup> Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Boston, MA

#### Abstract:

<u>Introduction:</u> This study aims to characterize attitudes towards COVID-19 vaccination and to evaluate factors associated with vaccine uptake amongst pregnant individuals.

Methods: An anonymous survey was distributed to a convenience sample of pregnant individuals receiving prenatal care at two large urban academic hospitals in a single healthcare network in Massachusetts. Individual demographic variables were included in the survey along with questions assessing attitudes towards COVID-19 and vaccination in pregnancy.

Results: Of 477 respondents, 233 (49.3%) had received or were scheduled to receive a COVID-19 vaccine. Age, White race, non-Hispanic/LatinX ethnicity, working from home, and typical receipt of the influenza vaccine were associated with COVID-19 vaccination. 276 respondents (58.4%) reported that their provider recommended the COVID-19 vaccine in pregnancy; these participants were more likely to have received a vaccine (OR 5.82, 95% confidence interval [CI] 3.68-9.26). Vaccinated individuals were less likely to be worried about the effects of the vaccine on themselves (OR 0.18, 95% CI 0.12-0.27) or their developing babies (OR 0.17, 95% CI 0.11-0.26). Unvaccinated individuals were less likely to report that it is easy to schedule a COVID-19 vaccine (OR 0.56, 95% CI 0.34-0.93), to travel to receive a vaccine (OR 0.19, 95% CI 0.10-0.36), and to miss work to receive a vaccine (OR 0.30, 95% CI 0.18-0.48).

<u>Conclusions:</u> Strategies are needed to improve patient education regarding vaccine side effects and safety in pregnancy and to change policy to make it feasible for pregnant patients to schedule and miss work without loss of pay to get vaccinated.

## **Key Points**:

- 1. There were racial and ethnic disparities in COVID-19 vaccination.
- 2. Unvaccinated respondents were more likely to be concerned about vaccine effects for themselves or their growing babies.
- Unvaccinated respondents cited work and scheduling-related barriers to vaccination, indicating areas for advocacy

Keywords: Pregnancy, vaccine hesitancy, racial disparities, COVID-19, vaccine barriers

5

6

9

10

11

13

15

16

17

18

20

21

22

23

4

may typically accept vaccines who have not yet been vaccinated against COVID-19.<sup>21</sup>

Furthermore, globally observed racial and ethnic disparities in COVID-19 vaccination, infection,

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

5

morbidity, and mortality persist in pregnant individuals and parallel that of the general population. <sup>20,22</sup> Understanding factors associated with vaccine hesitancy is thus vital to improve vaccination rates, curb infection-related morbidity and mortality, and reduce COVID-19 related disparities. Lack of inclusion of pregnant women in vaccine trials as well as lack of long-term safety data have been posited as reasons for low vaccine uptake in pregnancy.<sup>23-25</sup> However, factors associated with COVID-19 vaccine acceptance in pregnancy remain understudied. In this study, we surveyed pregnant and postpartum individuals in the outpatient setting to characterize perceptions and attitudes towards COVID-19 vaccination and to evaluate factors associated with vaccine uptake and vaccine hesitancy. Methods: **Participants** Survey participants were from a cross-sectional convenience sample of pregnant and postpartum individuals aged 18 or older receiving prenatal care at two large urban academic hospitals and three affiliated community health centers in a single healthcare network in Massachusetts from June to August 2021. Participants were approached by study staff during outpatient prenatal and ultrasound visits and were offered participation. Consent to participate in the survey was implied by voluntary participation in the anonymous survey. The study and survey instrument were approved by the Mass General Brigham IRB (protocol # 2021P001086).

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

6

Overall, 233 individuals (49.3%) had received or were scheduled to receive a COVID-19 vaccine. Participant demographics by vaccination status are shown in Table 1. Age, working from home, and typical receipt of the influenza vaccine were associated with COVID-19 vaccination. Individuals who identified as Hispanic/LatinX were less likely to be vaccinated than those who identified as non-Hispanic/Latinx (37.3% of Hispanic/LatinX vs 55.4% of non-Hispanic/LatinX, p=0.003 after adjustment for multiple comparisons). Respondents who identified as Black or African American were less likely than those who identified as White to be vaccinated (18.3% of Black or African American vs 62.6% of White respondents, p<0.001). Additionally, those who identified their race as Other or whose race was Unknown were less likely than those who identified as White to be unvaccinated (32.4% vs 62.6%, p<0.001 for Other vs White and 32.8% vs 62.6%, p<0.001 for Unknown vs White). There were no differences in vaccination rates between pregnant and postpartum individuals (50.1% of pregnant respondents vs 30.6% postpartum, p=0.16). 225 of the vaccinated respondents (96.5%) disclosed the type of vaccine they received: 214 (95.1%) had received one or both doses of an mRNA vaccine (either Pfizer or Moderna), 10 (4.4%) had received a J&J/Janssen viral vector vaccine, and 1 (0.4%) was unsure of their vaccine type. Of unvaccinated individuals (n=240), 14 (5.8%) planned to receive a vaccine during pregnancy. 276 respondents (58.4%) agreed or strongly agreed that their provider recommended the COVID-19 vaccine in pregnancy; these participants were more likely to have received a vaccine (OR 5.82, 95% confidence interval [CI] 3.68-9.26).

SARS-CoV-2 Infection Attitudes

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

Attitudes towards SARS-CoV2 infection between those who were unvaccinated and those who were vaccinated are shown in Figure 1. Vaccinated individuals were more likely than unvaccinated to agree or strongly agree that they feared COVID-19 during pregnancy, that if they were infected they were at risk for getting very sick, and that they knew someone who was hospitalized due to COVID-19. Those who were unvaccinated were more likely to agree or strongly agree that at some point in the pregnancy they believed they had SARS-CoV-2 infection and were more likely to have had a confirmed diagnosis of SARS-CoV-2 infection in pregnancy. One person in the cohort had been hospitalized due to COVID-19; that individual was not vaccinated.

Factors associated with Vaccine Hesitancy

Factors associated with vaccine hesitancy are shown in Figure 2. Unvaccinated individuals were more likely to agree or strongly agree that the vaccine was rushed and that they were worried about toxins in the vaccine. They were also more likely to agree or strongly agree that they were worried about the side effects of the vaccine for themselves or their baby or that the vaccine would cause them to contract COVID-19. Unvaccinated individuals were less likely to agree or strongly agree that they trust vaccine developers and that people of their race and ethnicity were included in vaccine trials. Vaccinated individuals were more likely to agree or strongly agree that the vaccine would protect them or their baby from becoming infected.

Barriers to Vaccination

Unvaccinated individuals were less likely to agree or strongly agree that it is easy to schedule a COVID-19 vaccine (OR 0.56, 95% CI 0.34-0.93), that it would be easy to travel to receive a

vaccine (OR 0.19, 95% CI 0.10-0.36), that it would be easy to miss work to receive a vaccine (OR 0.30, 95% CI 0.18-0.48), and that it would be easy to miss time with family to receive a vaccine (OR 0.27, 95% CI 0.16-0.43).

#### Effect of ACOG and CDC Statements

There were 35 respondents who completed the survey after the July 30, 2021 ACOG statement recommending COVID-19 vaccination in pregnancy and 23 who completed after the August 11, 2021 CDC statement recommending COVID-19 vaccination in pregnancy. There were no differences in self-reported vaccination rates in this cohort before and after the ACOG statement (p=0.98) or before and after the CDC statement (p=0.98). There were no changes to the above reported differences in baseline demographics, attitudes towards SARS-CoV2 infection, vaccine hesitancy, or barriers to vaccination after excluding those who responded after the ACOG statement (data not presented).

#### Discussion

In this cross-sectional study, only half of pregnant women reported receiving at least one dose of a COVID-19 vaccine, and few of those who had not been vaccinated planned to receive a vaccine during pregnancy. While this number is higher than the global and United States national reported rates of COVID-19 vaccination in pregnancy, it is lower than the Massachusetts adult vaccination rate of 63.6% at the time of this survey distribution and lower than this group's self-reported acceptance of influenza vaccination (74.7%). <sup>20,26</sup> These findings add to the growing body of evidence pointing towards suboptimal COVID-19 vaccination rates in pregnant individuals. Our findings are similar to the survey results by Sutton et al. in New York City,

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

which showed that pregnant respondents were less likely to accept vaccination compared with non-pregnant female respondents.<sup>25</sup> Similarly, Turocy et al. performed a survey of patients seeking fertility treatment and found that those who were planning pregnancy or currently pregnant were less likely to accept vaccination than those who were not planning pregnancy.<sup>27</sup> This may be because there is more vaccine hesitancy amongst pregnant individuals than nonpregnant individuals for vaccination in general. For example, prior studies have demonstrated suboptimal rates of influenza vaccination and Tdap vaccination in pregnancy, citing concerns about vaccine safety, lack of counseling, and disbelief in severity of disease. 21,28 Our study identified several factors associated with receipt of COVID-19 vaccination. Those who worked remotely were more likely to be vaccinated, whereas those who were not currently working were less likely to be vaccinated. Those who were vaccinated against COVID-19 were more likely to report that they typically receive the influenza vaccine, indicating that in general they are more accepting of vaccination. Importantly, there were racial and ethnic disparities in COVID-19 vaccination rates in this population. Only 42% of those who identified as Hispanic/LatinX and 19% of those who identified as Black and 32.4% of those who identified as Other reported receiving a vaccine, as compared with 55% of those who identified as non-Hispanic/LatinX and 64% of those who identified as White. Furthermore, those who had not received a vaccine were less likely to agree that people of their race and ethnicity were included in vaccine trials. These data mirror national trends in vaccination rates in non-pregnant individuals.<sup>4</sup> These findings highlight a need for

broader inclusion of individuals of non-White race in vaccine trials and vaccination campaigns to

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

ensure equitable access to and trust in vaccination. As has been previously argued, the burden of these disparities in vaccination rates should not fall on the patients but rather on the health systems and providers that initiate and preserve inequity and mistrust.<sup>29</sup> Survey respondents who had not received a COVID-19 vaccine were less likely to agree that they trusted vaccine developers and were more likely to feel that the vaccine was rushed. They were more worried about vaccine side effects and the effects of the vaccine on their developing fetus. These findings support the work by Skjefte et al., an international survey distributed electronically that found that pregnant individuals were worried about fetal effects, lack of safety data in pregnancy, and rushed development of vaccines.<sup>24</sup> Our study builds on these data by comparing concerns between pregnant persons who are and are not vaccinated. Unvaccinated individuals were more likely to have been infected by SARS-CoV-2 during pregnancy and less likely to be fearful of COVID-19 or to believe that if they contracted SARS-CoV-2 they were at risk of becoming very sick. These findings provide areas for improved patient counseling surrounding the risks of SARS-CoV-2 infection in pregnancy and the safety of vaccination, as post-approval studies have not shown more severe side effects in pregnant individuals or detrimental effects of the vaccine on pregnancies or fetal and neonatal outcomes.<sup>30,31</sup> They also highlight the importance of ongoing long-term follow-up studies to evaluate the health of children exposed to vaccination during pregnancy to provide families with long-term safety data. Respondents who were not vaccinated against COVID-19 identified several barriers to vaccination, including concerns about missing work or time with family as well as difficulty

scheduling a vaccine. These are thus areas for advocacy to diminish the effects of these logistical

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

barriers: vaccine recovery days could be protected and paid time off so that patients do not worry about missing time from work, vaccines can be mandated at workplaces to normalize vaccination and missing work to attend vaccine appointments, and they should be made available at expanded hours and at places that are frequently visited such as at workplaces and grocery stores.<sup>32-34</sup> Reducing some of these barriers to vaccination may lead to higher vaccination rates and reduced inequities in immunization status observed in our study and previous analyses. While most respondents in this study had discussed COVID-19 vaccination with their obstetric providers, just over half reported that their provider recommended COVID-19 vaccination in pregnancy. Given that provider confidence and recommendation of vaccination has consistently been shown to be a strong predictor of patient vaccination rates particularly in a pregnant population, it is imperative that providers feel comfortable engaging in conversations with patients surrounding immunization.<sup>35,36</sup> Now that the CDC and ACOG both recommend COVID-19 vaccination in pregnancy, providers should routinely discuss and recommend these vaccines to their patients with attention to addressing myths, misconceptions, and logistical barriers. National and institution-specific counseling guides may assist in the implementation of these recommendations. Strengths of this analysis include its large sample size and high response rate as well as diverse patient population. It is novel in its assessment of barriers to vaccination and comparisons of vaccination concerns amongst pregnant individuals who were and were not vaccinated. It was also conducted when all patients were eligible to receive vaccination, thus eliminating any

hesitation due to lack of eligibility. Limitations include that it was conducted when the CDC and

vaccination rates amongst pregnant individuals.

ACOG guidance was to offer, but not necessarily recommend, vaccination to pregnant patients. Acceptance of vaccination may be higher now that these organizations have provided stronger guidance regarding vaccination in pregnancy. Furthermore, the survey did not ask participants to differentiate their responses based on receipt or consideration of mRNA or viral vector vaccine, and it is possible that participants may have had different concerns depending on vaccine type.

Conclusions

Given the known increased risks of SARS-CoV-2 infection in pregnancy and the ongoing high case rates globally, vaccination of pregnant individuals is paramount to halting disease transmission and reducing barriers in SARS-CoV-2-related morbidity and mortality. An understanding of the factors associated with reduced vaccine uptake and the socioeconomic barriers to vaccination enables action to improve patient counseling and eliminate disparities in

## **Acknowledgements**

Dr. Gray has consulted for Illumina Inc,, Aetion, and BillionToOne outside the scope of the submitted work. No other financial disclosures are reported by the authors of this paper.

### References

- Ellington S, Strid P, Tong VT, et al. Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-June 7, 2020. MMWR Morb Mortal Wkly Rep 2020;69(25):769-775. DOI: 10.15585/mmwr.mm6925a1.
- Zambrano LD, Ellington S, Strid P, et al. Update: Characteristics of Symptomatic
   Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by
   Pregnancy Status United States, January 22-October 3, 2020. MMWR Morb Mortal
   Wkly Rep 2020;69(44):1641-1647. DOI: 10.15585/mmwr.mm6944e3.
- 3. Yap M, Debenham L, Kew T, et al. Clinical manifestations, prevalence, risk factors, outcomes, transmission, diagnosis and treatment of COVID-19 in pregnancy and postpartum: a living systematic review protocol. BMJ Open 2020;10(12):e041868. DOI: 10.1136/bmjopen-2020-041868.
- 4. Prevention CfDCa. COVID Data Tracker. (<a href="https://covid.cdc.gov/covid-data-tracker/#pregnant-population">https://covid.cdc.gov/covid-data-tracker/#pregnant-population</a>).
- 5. Woodworth KR, Olsen EO, Neelam V, et al. Birth and Infant Outcomes Following Laboratory-Confirmed SARS-CoV-2 Infection in Pregnancy - SET-NET, 16 Jurisdictions, March 29-October 14, 2020. MMWR Morb Mortal Wkly Rep 2020;69(44):1635-1640. DOI: 10.15585/mmwr.mm6944e2.
- 6. Rajewska A, Mikolajek-Bedner W, Lebdowicz-Knul J, Sokolowska M, Kwiatkowski S, Torbe A. COVID-19 and pregnancy where are we now? A review. J Perinat Med 2020;48(5):428-434. DOI: 10.1515/jpm-2020-0132.

- 7. Wei SQ, Bilodeau-Bertrand M, Liu S, Auger N. The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis. CMAJ 2021;193(16):E540-E548. DOI: 10.1503/cmaj.202604.
- Narang K, Enninga EAL, Gunaratne M, et al. SARS-CoV-2 Infection and COVID-19
   During Pregnancy: A Multidisciplinary Review. Mayo Clin Proc 2020;95(8):1750-1765.
   DOI: 10.1016/j.mayocp.2020.05.011.
- 9. Di Mascio D, Sen C, Saccone G, et al. Risk factors associated with adverse fetal outcomes in pregnancies affected by Coronavirus disease 2019 (COVID-19): a secondary analysis of the WAPM study on COVID-19. J Perinat Med 2020;48(9):950-958. DOI: 10.1515/jpm-2020-0355.
- 10. Di Mascio D, Khalil A, Saccone G, et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM 2020;2(2):100107. DOI: 10.1016/j.ajogmf.2020.100107.
- 11. Beigi RH, Krubiner C, Jamieson DJ, et al. The need for inclusion of pregnant women in COVID-19 vaccine trials. Vaccine 2021;39(6):868-870. DOI: 10.1016/j.vaccine.2020.12.074.
- 12. Maykin MM, Heuser C, Feltovich H. Pregnant people deserve the protection offered by SARS-CoV-2 vaccines. Vaccine 2021;39(2):171-172. (In eng). DOI: 10.1016/j.vaccine.2020.12.007.
- 13. Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. N Engl J Med 2021;384(24):2273-2282. DOI: 10.1056/NEJMoa2104983.

- 14. Zauche LH, Wallace B, Smoots AN, et al. Receipt of mRNA COVID-19 vaccines preconception and during pregnancy and risk of self-reported spontaneous abortions, CDC v-safe COVID-19 Vaccine Pregnancy Registry 2020-21. Res Sq 2021. DOI: 10.21203/rs.3.rs-798175/v1.
- Goldshtein I, Nevo D, Steinberg DM, et al. Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women. JAMA 2021. DOI: 10.1001/jama.2021.11035.
- 16. Gray KJ, Bordt EA, Atyeo C, et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol 2021. DOI: 10.1016/j.ajog.2021.03.023.
- 17. Statistics CfDC-NCfH. COVID-19 Vaccines While Pregnant or Breastfeeding.

  (https://www.cdc.gov/coronavirus/2019ncov/vaccines/recommendations/pregnancy.html).
- 18. Force SC-T. SMFM: Provider Considerations for Engaging in COVID-10 Vaccine

  Counseling with Pregnant and Lactating Patients.

  (https://s3.amazonaws.com/cdn.smfm.org/media/3070/Provider\_Considerations\_for\_Engaging\_in\_COVID\_Vaccination\_Considerations\_8-13-21\_%28final%29\_.pdf).
- 19. ACOG Immunization ID, and Public Health Preparedness Expert Work Group. COVID-19 Vaccination Considerations for Obstetric-Gynecologic Care. ACOG.org: ACOG, July 30, 2021 2021. (<a href="https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care">https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care</a>).

- 20. Razzaghi H, Meghani M, Pingali C, et al. COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 8, 2021. MMWR Morb Mortal Wkly Rep 2021;70(24):895-899. DOI: 10.15585/mmwr.mm7024e2.
- 21. Razzaghi H KK, Black CL, et al. Influenza and Tdap Vaccination Coverage Among Pregnant Women United States, April 2020.
- 22. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ 2020;370:m3320. DOI: 10.1136/bmj.m3320.
- 23. Goncu Ayhan S, Oluklu D, Atalay A, et al. COVID-19 vaccine acceptance in pregnant women. Int J Gynaecol Obstet 2021;154(2):291-296. DOI: 10.1002/ijgo.13713.
- 24. Skjefte M, Ngirbabul M, Akeju O, et al. COVID-19 vaccine acceptance among pregnant women and mothers of young children: results of a survey in 16 countries. Eur J Epidemiol 2021;36(2):197-211. DOI: 10.1007/s10654-021-00728-6.
- 25. Sutton D, D'Alton M, Zhang Y, et al. COVID-19 vaccine acceptance among pregnant, breastfeeding, and nonpregnant reproductive-aged women. Am J Obstet Gynecol MFM 2021;3(5):100403. DOI: 10.1016/j.ajogmf.2021.100403.
- 26. Mass.gov. Massachusetts COVID-19 Vaccination Data and Updates

  (https://www.mass.gov/info-details/massachusetts-covid-19-vaccination-data-and-updates#daily-covid-19-vaccine-report-).
- 27. Turocy J RA, Reshef E, D'Alton M, Forman E, Williams Z. A Survey of Fertility Patients' Attitudes Towards the COVID-19 Vaccine. Fertility & Sterility 2021

- (https://www.fertstertdialog.com/posts/a-survey-of-fertility-patients-attitudes-towards-the-covid-19-vaccine).
- 28. Van Buynder PG, Van Buynder JL, Menton L, Thompson G, Sun J. Antigen specific vaccine hesitancy in pregnancy. Vaccine 2019;37(21):2814-2820. (In eng). DOI: 10.1016/j.vaccine.2019.04.021.
- 29. Corbie-Smith G. Vaccine Hesitancy is a Scapegoat for Structural Racism. Jama Health Forum 2021 (<a href="https://jamanetwork.com/channels/health-forum/fullarticle/2778073">https://jamanetwork.com/channels/health-forum/fullarticle/2778073</a>).
- 30. Garg I, Shekhar R, Sheikh AB, Pal S. COVID-19 Vaccine in Pregnant and Lactating Women: A Review of Existing Evidence and Practice Guidelines. Infect Dis Rep 2021;13(3):685-699. (In eng). DOI: 10.3390/idr13030064.
- 31. Stafford IA, Parchem JG, Sibai BM. The coronavirus disease 2019 vaccine in pregnancy: risks, benefits, and recommendations. Am J Obstet Gynecol 2021;224(5):484-495. (In eng). DOI: 10.1016/j.ajog.2021.01.022.
- 32. Coley KC, Gessler C, McGivney M, Richardson R, DeJames J, Berenbrok LA.

  Increasing adult vaccinations at a regional supermarket chain pharmacy: A multi-site demonstration project. Vaccine 2020;38(24):4044-4049. (In eng). DOI: 10.1016/j.vaccine.2020.02.040.
- 33. Zhai Y, Santibanez TA, Kahn KE, Black CL, de Perio MA. Paid sick leave benefits, influenza vaccination, and taking sick days due to influenza-like illness among U.S. workers. Vaccine 2018;36(48):7316-7323. (In eng). DOI: 10.1016/j.vaccine.2018.10.039.
- 34. Gessler CA, Richardson RM, Hall DL, Coley KC. Operationalizing Pandemic Vaccinations at a Regional Supermarket Chain Pharmacy. Disaster Med Public Health Prep 2021:1-6. (In eng). DOI: 10.1017/dmp.2021.43.

- 35. Paterson P, Meurice F, Stanberry LR, Glismann S, Rosenthal SL, Larson HJ. Vaccine hesitancy and healthcare providers. Vaccine 2016;34(52):6700-6706. DOI: 10.1016/j.vaccine.2016.10.042.
- 36. Wilson RJ, Paterson P, Jarrett C, Larson HJ. Understanding factors influencing vaccination acceptance during pregnancy globally: A literature review. Vaccine 2015;33(47):6420-9. DOI: 10.1016/j.vaccine.2015.08.046.

## Figure 1: Attitudes Towards SARS-CoV2

Caption:\*OR is relative to unvaccinated

# Figure 2: Factors Associated with Vaccine Hesitancy

Caption: \*OR is relative to unvaccinated

## **Table 1: Demographic Characteristics by Vaccination Status**

		23	
	Vaccinated	Unvaccinated	P-value
	(n=233)	(n=240)	
Age, mean y (SD)	33.0 (4.5)	31.4 (5.6)	<0.005
Ethnicity, n (%)			0.002
Non-Hispanic/Latinx	158 (67.8%)	127 (52.9%)	
(n=285)			
Hispanic/Latinx (n=134)	50 (21.5%)	84 (35.0%)	
Hispanic/Launx (II–154)	30 (21.370)	04 (33.070)	
Unknown (n=54)	25 (10.7%)	29 (12.1%)	
Race, n (%)			<0.005
American Indian or	0 (0%)	3 (1.3%)	
Alaska Native (n=3,			
0.63%)			
,			
Asian (n=36, 7.6%)	17 (7.3%)	19 (7.9%)	
Black or African	11 (4.7%)	49 (20.4%)	
American (n=60, 12.7%)			
American (n=00, 12.770)			
Native Hawaiian or	1 (0.4%)	0 (0%)	
Pacific Islander (n=1,			
0.20/)			
0.2%)			
White (n=275, 58.1%)	172 (73.8%)	103 (42.9%)	
Other (n=37, 7.8%)	12 (5.2%)	25 (10.4%)	
		, ,	
Unknown (n=61, 12.9%)	20 (8.6%)	41 (17.1%)	

Number of People in	2.96 (1.3)	3.20 (1.5)	0.07
Household, mean (SD)			
Work Location n (%)			<0.005
Working remotely	87 (37.3%)	52 (21.7%)	
(n=139)			
Working in person	67 (28.8%)	78 (32.5%)	
(n=145)			
Working both remotely	40 (17.2%)	28 (11.7%)	
and in person (n=68)			
Not currently working	38 (16.3%)	77 (32.1%)	
(n=115)			
Unknown (n=6)	1 (.43%)	5 (2.1%)	
Any medical	50 (21.5%)	47 (19.6%)	0.66
comorbidities, n (%) *			
Typically receive	201 (86.2%)	149 (62.1%)	<0.005
influenza vaccination, n			
(%)			

<sup>\*</sup>Medical comorbidities were defined as self-report of cancer, renal disease, asthma, obesity,

heart disease, hypertension, immune compromise, diabetes, sickle cell disease

Factors associated with vaccine hesitancy	Unvaccinated	Vaccinated				Odds Ratio with 95% CI		
Feel the vaccine was rushed	92	22	-				0.16 [ 0.10,	0.27]
Trust vaccine developers	80	174				-	6.52 [ 4.30,	9.91]
Believe people of their race and ethnicity were included in vaccine trials	92	149			-	H	2.65 [ 1.79,	3.92]
Worried about the side effects of the vaccine for themselves	159	64	-				0.18 [ 0.12,	0.27]
Worried about the side effects of the vaccine for their baby	175	77	-				0.17 [ 0.11,	0.25]
Believe the vaccine will cause them to contract COVID-19	22	5					0.21 [ 0.08,	0.56]
Worried about toxins in the vaccine	72	21		_			0.22 [ 0.13,	0.38]
Believe the vaccine will protect them from getting COVID-19	80	189				-	10.75 [ 6.73,	17.17]
Believe the vaccine will protect their baby from getting COVID-19	62	155				-	6.36 [ 4.16,	9.73]
				4.00			<u>==</u> }	
			1/8	1/2	2	8		

